BLC
SUPN icon

Brown, Lisle/Cummings’s Supernus Pharmaceuticals SUPN Stock Holding History

Brown, Lisle/Cummings’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698 Sell
15
-12
-44% -$576 ﹤0.01% 991
2026
Q1 		$1.4K Buy
+27
New +$1.38K ﹤0.01% 887

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Brown, Lisle/Cummings's SUPN Position: Q2 2026 in Review

Brown, Lisle/Cummings reduced its Supernus Pharmaceuticals (SUPN) stake by 44% in Q2 2026, selling an estimated $576 and leaving 15 shares worth $698. The position accounts for ﹤0.01% of the portfolio, ranked #991.

Brown, Lisle/Cummings first reported a position in SUPN in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.4K in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Brown, Lisle/Cummings held 15 shares of Supernus Pharmaceuticals worth $698 as of Q2 2026.
  • Brown, Lisle/Cummings sold 12 Supernus Pharmaceuticals shares in Q2 2026, an estimated $576.
  • Supernus Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #991 holding.
  • Brown, Lisle/Cummings first reported a position in Supernus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Brown, Lisle/Cummings's Supernus Pharmaceuticals position peaked at $1.4K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.